NEW STUDY Circulating suPAR associates with severity and in-hospital progression of COVID-19 BACKGROUND: COVID-19 disease progression is characterized by hyper inflammation, and risk stratification may aid in early aggressive treatment and advanced planning. The aim [...]
NEW STUDY High blood sugar and suPAR levels independently worsen COVID-19 outcomes The largest study to investigate the role of inflammatory biomarkers in hospitalized COVID-19 patients uncovers risk factors for worse health outcomes in those with diabetes. [...]
NEW STUDY Soluble urokinase receptor and mortality in kidney transplant recipients A recent study from Heidelberg University Hospital investigated the value of suPAR for the prediction of cardiovascular events and cardiovascular mortality in [...]
NEW ARTICLE Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19 Objective Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that [...]
Key highlights from the study Results showed a 70% decrease in the relative risk of progression to severe respiratory failure and a significant reduction in 28-d mortality with anakinra treatment compared to standard of care. [...]
NEW ARTICLE suPAR independently predicts severity and length of hospitalisation in patients with COVID-19 Efficient healthcare based on prognostic variables in hospitalised patients with COVID-19 could reduce the risk of complications and death. [...]
Frontiers in Immunology publication: suPAR as a Biomarker of Systemic Chronic Inflammation 10 properties and characteristics that are shared by the blood protein suPAR and SCI, supporting the argument that suPAR is a biomarker of SCI [...]
NEW STUDY Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery A recent prospective observational study has investigated whether suPAR [...]
New Webinar
